All News
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
💡Screen pts with Ssc for ILD with HRCT at diagnosis.
💡“MCTD” may meet criteria for Ssc dont look away at the positive U1RNP!
💡Kidney biopsy in SRC =Time is of the essence.
💡Cardiac involvement is 2nd cause of mortality screen with echo annually. @fboinMD #ACR23 @RheumNow https://t.co/yp3yjqqeQv
Adela Castro AdelaCastro222 ( View Tweet)
Assessment of organ involvement in scleroderma by Boin F, a great example of great clearly presented slides #ACR23 @RheumNow https://t.co/zMwY1NGpYI
Dr. Antoni Chan ( View Tweet)
The message about scleroderma we need to keep on saying to those outside of rheumatology:
you can get severe organ involvement in both limited & diffuse SSc
survival is dictated by organ involvement
screening is needed regardless!
Francesco Boin #ACR23 Review Course @RheumNow https://t.co/otUPjWNVoo
David Liew drdavidliew ( View Tweet)
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/W6F736uskO https://t.co/u1IZnIy7wg
Dr. John Cush RheumNow ( View Tweet)
Sleep Apnea Smart Watches (10.13.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Read Article
342 systemic sclerosis pts, ~32% report reproductive probs:
-early menopause onset (45 vs 48y)
-menopause effected by SSc onset & digital ulcers
-More spont Abs(12 vs 4%), premies (22 vs 6%), low birth Wt (27 vs 5%), C-section (49 vs 19%); NOT Infertility https://t.co/Tjjl9sxtja https://t.co/LKzyGR0mlE
Dr. John Cush RheumNow ( View Tweet)
Hard Decisions in RA (9.1.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article
Manifestations of Systemic Sclerosis Sine Scleroderma
Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%).
Read Article
Mono- and Oligo- are Different (8.18.2023)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Read Article
Pizza and Rheumatoid Arthritis (8.11.2023)
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Read Article
Johns Hopkins & Univ Pittsburgh Scleroderma compared autoantibodies in 676 SSc pts w/ hx of cancer to 687 SSc controls without CA. Anti-POLR3 & anti-Ro52 assoc w. significantly increased cancer risk; Centromere & U1RNP had a decreased cancer risk https://t.co/z6HfRR7PWs https://t.co/zISZlgHGjd
Links:
Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc.
https://t.co/DMZTLKwmHv https://t.co/2bXqMt7H1z
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Links:
Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc.
https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241
Dr. John Cush RheumNow ( View Tweet)